Reuters: Astellas sees U.S. delay on transplant drug Advagraf

[NaDiNe]

Astellas sees U.S. delay on transplant drug Advagraf
      

TOKYO (Reuters) - Japan's Astellas Pharma Inc said on Friday that U.S. authorities have requested more information on its key kidney transplant drug Advagraf, meaning it will face further delays in receiving approval there.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login